Skip to main content
. 2021 Nov 12;205(2):198–207. doi: 10.1164/rccm.202107-1766OC

Table 1.

Baseline Characteristics for Patients with One Event and More Than One Event

  1 Event
>1 Event
Total (n = 198)
  Inhaled Treprostinil (n = 54) Placebo (n = 51) Inhaled Treprostinil (n = 35) Placebo (n = 58)
Female, n (%) 28 (52%) 19 (37%) 18 (51%) 28 (48%) 93 (47%)
Age, yr, mean (SD) 64 (14) 68 (11) 68 (11) 67 (11) 67 (12)
White, n (%) 39 (72%) 42 (82%) 24 (69%) 42 (72%) 147 (74%)
BMI, kg/m2, mean (SD) 30.2 (7.4) 28.9 (6.3) 29.7 (5.7) 27.9 (5.4) 29.1 (6.3)
Years since PH-ILD diagnosis, mean (SD) 0.5 (0.7) 0.3 (0.3) 0.6 (1.2) 0.7 (1.3) 0.5 (1.0)
Disease etiology, n (%)          
 IIP 25 (46%) 29 (57%) 11 (31%) 26 (45%) 91 (46%)
  IPF only 16 (30%) 20 (39%) 7 (20%) 16 (28%) 59 (30%)
 CPFE 11 (20%) 7 (14%) 12 (34%) 17 (29%) 47 (24%)
 CTD-ILD 16 (30%) 11 (22%) 6 (17%) 13 (22%) 46 (23%)
6-min-walk distance, m, mean (SD) 247 (99) 273 (89) 211 (80) 235 (92) 244 (93)
NT-proBNP, pg/ml, mean (SD) 1,991 (3,349) 931 (1,257) 2,431 (2,985) 3,130 (4,382) 2,123 (3,343)
Hemodynamics, mean (SD)          
 PAPm, mm Hg 38.4 (9.8) 35.0 (7.9) 38.8 (9.7) 37.1 (8.9) 37.2 (9.1)
 PCWP, mm Hg 10.6 (3.4) 9.8 (3.1) 10.4 (3.7) 9.9 (3.8) 10.1 (3.5)
 PVR, Wood units 6.5 (3.2) 5.6 (2.2) 6.7 (2.5) 6.6 (3.3) 6.4 (2.9)
Lung function tests, mean (SD)          
 TLC % predicted 62 (16) 65 (21) 62 (18) 65 (16) 63 (16)
 FVC % predicted 60 (19) 63 (22) 61 (19) 63 (20) 62 (20)
 FEV1% predicted 61 (19) 65 (21) 61 (20) 65 (20) 63 (20)
 DlCO % predicted 30 (12) 29 (10) 29 (13) 25 (13) 28 (12)

Definition of abbreviations: BMI = body mass index; CPFE = combined pulmonary fibrosis and emphysema; CTD-ILD = connective tissue disease–associated interstitial lung disease; IIP = idiopathic interstitial pneumonia; IPF = idiopathic pulmonary fibrosis; NT-proBNP = N-terminal pro–brain natriuretic peptide; PAPm = mean pulmonary arterial pressure; PCWP = pulmonary capillary wedge pressure; PH-ILD = interstitial lung disease complicated by pulmonary hypertension; PVR = pulmonary vascular resistance.